AR038957A1 - Terapia de combinacion para el tratamiento del cancer - Google Patents

Terapia de combinacion para el tratamiento del cancer

Info

Publication number
AR038957A1
AR038957A1 ARP020103071A ARP020103071A AR038957A1 AR 038957 A1 AR038957 A1 AR 038957A1 AR P020103071 A ARP020103071 A AR P020103071A AR P020103071 A ARP020103071 A AR P020103071A AR 038957 A1 AR038957 A1 AR 038957A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
hydrogen
aryl
substituted alkyl
Prior art date
Application number
ARP020103071A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Sugen Inc filed Critical Pharmacia Corp
Publication of AR038957A1 publication Critical patent/AR038957A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Un método para tratar o prevenir el cáncer que comprende administrar a un mamífero que necesita tal tratamiento una cantidad eficaz para el uso terapéutico de un inhibidor de la protein quinasa de formula (1), donde: R se selecciona del grupo que consiste en hidrógeno, piperazin-1-ilmetilo, 4-metilpiperazin-1-ilmetilo, piperidin-1-ilmetilo, 2-hidroximetilpirrolidin-1-ilmetilo, 2-carboxipirrolidin-1-ilmetilo, y pirrolidin-1-ilmetilo; R1 se selecciona del grupo que consiste en hidrógeno, halo, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, heteroarilo, heteroalicíclico, hidroxi, alcoxilo, C(O)NR8R9, -NR13R14, -(CO)R15, y -(CH2)R16; R2 se selecciona del grupo que consiste de hidrógeno, halo alquilo, alquilo sustituido, trihalometilo, hidroxi, alcoxi, ciano, -NR13R14, -NR13C(O)R14; -C(O)R15, arilo, heteroarilo, y -S(O)2NR13R14; R3 se selecciona del grupo que consiste en hidrógeno, halógeno, alquilo, alquilo sustituido, trihalometilo, hidroxi, alcoxi, arilo, heteroarilo, -NR13R14, -NR13S(O)2R14, -S(O)2NR13R14, -NR13C(O)R14, -NR13C(O)OR14, -(CO)R15, y -SO2R19; R4 se selecciona del grupo que consiste de hidrógeno, halógeno, alquilo, alquilo sustituido, hidroxi, alcoxi, y -NR13R14; R5 se selecciona del grupo que consiste en hidrógeno, alquilo, alquilo sustituido, y -C(O)R10; R6 se selecciona del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, y -C(O)R10; R7 se selecciona del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, arilo, heteroarilo, -C(O)R17, y -C(O)R10, teniendo en cuenta que cuando R es hidrógeno, al menos uno de R5, R6 y R7 es -C(O)R10; o R6 y R7 pueden combinarse para formar un grupo seleccionado del grupo que consiste de -(CH2)4-, -(CH2)5- y -(CH2)6-; R8 y R9 se seleccionan independientemente del grupo que consiste en hidrógeno, alquilo, alquilo sustituido, y arilo; R10 se selecciona del grupo que consiste de hidroxilo, alcoxilo, ariloxilo, -N(R11)(alquileno)nR12, donde el grupo alquileno está opcionalmente sustituido con un grupo hidroxilo, y -NR13R14; R11 se selecciona del grupo que consiste de hidrógeno, alquilo, y alquilo sustituido; R12 se selecciona del grupo que consiste de -NR13R14, hidroxi, -C(O)R15, arilo, heteroarilo, -N+(O-)R13R14, -N(OH)R13, y -NHC(O)R18 (donde R18 es alquilo, alquilo sustituido, haloalquilo, o aralquilo); R13 y R14 se seleccionan independientemente del grupo que consiste en hidrógeno, alquilo, alquilo sustituido, alquilo inferior sustituido con hidroxialquilamino, cianoalquilo, cicloalquilo, cicloalquilo sustituido, arilo y heteroarilo; ó R13 y R14 pueden combinarse para formar un grupo heterociclo; R15 se selecciona del grupo que consiste en hidrógeno, hidroxi, alcoxi y ariloxilo; R16 se selecciona del grupo que consiste de hidroxilo, -NR13R14, -C(O)R15, y -C(O)NR13R14; R17 se selecciona del grupo que consiste en alquilo, alquilo sustituido, cicloalquilo, arilo y heteroarilo; R19 se selecciona del grupo que consiste en alquilo, alquilo sustituido, arilo, aralquilo, heteroarilo, o heteroaralquilo; y n y r son independientemente 1, 2, 3, ó 4; en combinación con un inhibidor de ciclooxigenasa; o una sal del mismo aceptable para el uso farmacéutico. Preferentemente el inhibidor de proteína quinasa de fórmula (1) se usa en combinación con un inhibidor selectivo de ciclooxigenasa-2. Un beneficio del método es que las terapias se administran en combinación a una dosis baja, es decir, una dosis menor que la que se usa convencionalmente en situaciones clínicas, de cada uno de los componentes administrados solos. Un beneficio de disminuir la dosis de las terapias administradas a mamíferos incluye una disminución en la incidencia de efectos adversos asociados con dosis mayores.
ARP020103071A 2001-08-15 2002-08-14 Terapia de combinacion para el tratamiento del cancer AR038957A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31241301P 2001-08-15 2001-08-15

Publications (1)

Publication Number Publication Date
AR038957A1 true AR038957A1 (es) 2005-02-02

Family

ID=23211320

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103071A AR038957A1 (es) 2001-08-15 2002-08-14 Terapia de combinacion para el tratamiento del cancer

Country Status (36)

Country Link
US (1) US7320996B2 (es)
EP (1) EP1427326B1 (es)
JP (1) JP2005501843A (es)
KR (1) KR100656004B1 (es)
CN (1) CN1541098A (es)
AP (1) AP2004002995A0 (es)
AR (1) AR038957A1 (es)
AT (1) ATE414512T1 (es)
AU (1) AU2002329744B2 (es)
BG (1) BG108622A (es)
BR (1) BR0211978A (es)
CA (1) CA2457745A1 (es)
CO (1) CO5560544A2 (es)
CZ (1) CZ2004356A3 (es)
DE (1) DE60229959D1 (es)
EA (1) EA008137B1 (es)
EC (1) ECSP045021A (es)
GE (1) GEP20063868B (es)
HR (1) HRP20040170A2 (es)
HU (1) HUP0500424A3 (es)
IL (1) IL159887A0 (es)
IS (1) IS7137A (es)
MA (1) MA27060A1 (es)
MX (1) MXPA04001464A (es)
NO (1) NO20040516L (es)
NZ (1) NZ530792A (es)
OA (1) OA12651A (es)
PE (1) PE20030332A1 (es)
PL (1) PL368921A1 (es)
RS (1) RS13204A (es)
SK (1) SK1412004A3 (es)
TN (1) TNSN04015A1 (es)
TW (1) TWI230609B (es)
UA (1) UA77002C2 (es)
WO (1) WO2003015608A2 (es)
ZA (1) ZA200400849B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045307A2 (en) * 2001-11-21 2003-06-05 Sugen, Inc. Pharmaceutical formulations comprising indolinone derivatives
US6747025B1 (en) 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
AU2003295658A1 (en) * 2002-11-27 2004-06-23 Allergan, Inc. Indol derivatives and their use as kinase inhibitors
RS20050430A (en) 2002-12-19 2007-08-03 Pfizer Inc., 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
BRPI0415111A (pt) * 2003-10-08 2006-11-28 Novartis Ag composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
RU2007141654A (ru) * 2005-05-12 2009-05-20 Пфайзер Инк. (US) Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат
US20070015728A1 (en) * 2005-07-08 2007-01-18 Ford John P Metered-dose and safety and compliance packaging for systemic anticancer therapy
US7928136B2 (en) 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2009030270A1 (en) * 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
GB0813873D0 (en) * 2008-07-30 2008-09-03 Univ Dundee Compounds
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
RU2495628C1 (ru) * 2012-04-18 2013-10-20 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ выбора тактики лечения актинического кератоза
TWI646091B (zh) * 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
RU2015143526A (ru) * 2013-03-13 2017-04-19 Бостон Байомедикал, Инк. Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака
CN103923014A (zh) * 2014-05-05 2014-07-16 宁夏宝马药业有限公司 环肌酸制备方法
JP6942726B2 (ja) 2016-01-08 2021-09-29 ユークリセス ファーマシューティカルズ，インコーポレイテッド クロメン化合物および第２活性薬剤の併用薬
CN111759883B (zh) * 2020-07-23 2021-09-17 浙江农林大学 山核桃内果皮提取物在制备抗卵巢癌产品中的应用
CN114853736B (zh) * 2022-07-06 2022-10-21 北京鑫开元医药科技有限公司 具有trk抑制活性的化合物、制备方法、组合物及其用途

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE553661A (es) * 1955-12-23
US3840597A (en) 1971-02-24 1974-10-08 Riker Laboratories Inc Substituted 2-phenoxy alkane-sulfonanilides
US4002749A (en) * 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
US4053613A (en) * 1975-09-17 1977-10-11 E. R. Squibb & Sons, Inc. 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones
DE2756113A1 (de) 1977-12-16 1979-06-21 Thomae Gmbh Dr K Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3310891A1 (de) * 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
DE3426419A1 (de) * 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
DD290192A5 (de) 1986-11-13 1991-05-23 Eisai Co. Ltd,Jp Pyridinderivat mit antiulzeroeser wirkung
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
GB8816944D0 (en) * 1988-07-15 1988-08-17 Sobio Lab Compounds
RU2034842C1 (ru) 1989-07-25 1995-05-10 Алкалоида Ведьесети Дьяр Производные хинолина и способ их получения
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5196446A (en) * 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
FR2672596B1 (fr) 1991-02-07 1995-07-13 Roussel Uclaf Nouveaux derives bicycliques azotes, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
FR2676444B1 (fr) 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
US5124347A (en) * 1991-07-31 1992-06-23 Warner-Lambert Co. 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents
US5322950A (en) * 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
US5389661A (en) * 1991-12-05 1995-02-14 Warner-Lambert Company Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties
FR2694004B1 (fr) * 1992-07-21 1994-08-26 Adir Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
DK0595546T3 (da) 1992-10-28 1996-04-15 Shionogi & Co Benzylidenderivater
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
CA2243199C (en) 1993-01-15 2005-08-02 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
FR2701260B1 (fr) 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
EP0696272A1 (en) 1993-04-27 1996-02-14 The Wellcome Foundation Limited Cyclooxygenase and 5-lipoxygenase inhibiting n(3-biphenylyl-1(s)-methyl-2-propenyl) acetohydroxamic acid derivatives
WO1994026731A1 (en) 1993-05-13 1994-11-24 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
DE69432193T2 (de) 1993-11-30 2004-01-15 Searle & Co Substituierte Pyrazolyl-benzolsulfonamide und ihre Verwendung als CyclooxygenaseII Inhibitoren
US5475018A (en) 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
DK0743938T3 (da) 1994-02-10 1999-10-25 Searle & Co Substituerede spiroforbindelser til behandling af inflammation
US5418254A (en) 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
WO1995030652A1 (en) 1994-05-04 1995-11-16 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
EP1125932A3 (en) 1994-07-27 2001-08-29 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
RU2128175C1 (ru) 1994-08-09 1999-03-27 Эйсай Ко., Лтд. Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
GB2294879A (en) 1994-10-19 1996-05-15 Merck & Co Inc Cylcooxygenase-2 Inhibitors
DE69512930T2 (de) 1994-10-27 2000-05-18 Merck Frosst Canada Inc Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
US5739166A (en) 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
JP3181190B2 (ja) 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
JP2636819B2 (ja) 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
ES2191069T3 (es) 1994-12-21 2003-09-01 Merck Frosst Canada Inc Diaril-2-(5h)-furanonas como inhibidores de cox-2.
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
CA2211320C (en) 1995-01-31 2007-03-20 Merck Frosst Canada Inc. 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
US5596008A (en) 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5686470A (en) 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
ATE223390T1 (de) 1995-02-13 2002-09-15 Searle & Co Substituierte isoxazole zur behandlung von entzündung
US5955505A (en) 1995-02-21 1999-09-21 Nippon Suisan Kaisha, Ltd. Glutamic acid receptor agonist
SK133297A3 (en) 1995-04-04 1998-07-08 Glaxo Group Ltd Imidazo[1,2-a]pyridine derivatives, pharmaceutical composition containing same and their use
GB9507298D0 (en) * 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
CA2221692A1 (en) 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
WO1996038418A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CA2224563A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
JPH11507670A (ja) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターと５−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
CA2180624C (en) 1995-07-12 2006-12-12 Cheuk Kun Lau Diphenyl-1,2,3-thiadiazoles as anti-inflammatory agents
GB9514518D0 (en) 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
NZ312997A (en) 1995-07-19 2000-07-28 Merck & Co Inc use of a non-steroidal anti-inflammatory agent for treating colonic adenomas
WO1997011701A1 (en) 1995-09-27 1997-04-03 Merck-Frosst Canada Inc. Compositions for treating inflammation containing certain prostaglandins and a selective cyclooxygenase-2 inhibitor
GB9520584D0 (en) 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
US6376733B1 (en) 1996-01-25 2002-04-23 Exxonmobil Chemical Patents Inc. Process for production of paraxylene
EP0882015B1 (en) 1996-02-01 2000-12-27 Merck Frosst Canada & Co. Diphenyl stilbenes as prodrugs to cox-2 inhibitors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
ES2147973T3 (es) 1996-02-01 2000-10-01 Merck Frosst Canada Inc Estirenos alquilatados como profarmacos de inhibidores de cox-2.
WO1997029774A1 (en) 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
PT880362E (pt) 1996-02-13 2005-10-31 Searle & Co Composicoes compreendendo um inibidor do cicloxigenase tipo 2 e um antagonista do receptor do leucotrieno b4
CA2246265A1 (en) 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
US6180651B1 (en) 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
ATE408607T1 (de) 1996-04-12 2008-10-15 Searle Llc Substituierte benzensulfonamid-derivate als wirkstoff-vorläufer von cox-2 inhibitoren
WO1997041824A2 (en) * 1996-05-03 1997-11-13 Abbott Laboratories Antiangiogenic peptides derived from plasminogen
US5677318A (en) 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751966B1 (fr) 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751964B1 (fr) 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
US5830911A (en) 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US5681842A (en) 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
US5869524A (en) 1996-11-12 1999-02-09 American Home Products Corporation Indene inhibitors of COX-2
JPH10158234A (ja) 1996-12-02 1998-06-16 Kotobuki Seiyaku Kk ２−フェニルアズレン誘導体及びその製造方法
PT846689E (pt) 1996-12-09 2004-06-30 Pfizer Compostos de benzimidazole
JP4167733B2 (ja) 1996-12-16 2008-10-22 花王株式会社 ＮＦ−κＢ活性化抑制剤
EP0863134A1 (en) 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
FR2769311B1 (fr) 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
FR2770131A1 (fr) 1997-10-27 1999-04-30 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
GB2330833A (en) 1997-10-29 1999-05-05 Merck & Co Inc PREPARATION OF 4-(4-Methylsulfonylphenyl)-2-furanones USEFUL AS COX-2 INHIBITORS
FR2771005B1 (fr) 1997-11-18 2002-06-07 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
FR2771412B1 (fr) 1997-11-26 2000-04-28 Adir Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TR200003514T2 (tr) 1998-05-29 2002-05-21 Sugen Inc. Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
AU760964B2 (en) * 1998-12-31 2003-05-22 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy
MXPA02006263A (es) * 1999-12-22 2004-02-26 Sugen Inc Metodos de modulacion de la funcion de la cinasa de tirosina c-kit de la proteina con compuestos de indolinona.
JP2003535038A (ja) * 1999-12-30 2003-11-25 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
ME00415B (me) * 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori
DE60128673D1 (de) * 2000-03-17 2007-07-12 Avocet Polymer Technologies In Verfahren zur verbesserung der grösse und des aussehens einer wunde

Also Published As

Publication number Publication date
BG108622A (bg) 2005-10-31
ZA200400849B (en) 2005-05-03
US7320996B2 (en) 2008-01-22
CO5560544A2 (es) 2005-09-30
EP1427326B1 (en) 2008-11-19
TWI230609B (en) 2005-04-11
PL368921A1 (en) 2005-04-04
CZ2004356A3 (cs) 2004-12-15
ECSP045021A (es) 2004-04-28
KR100656004B1 (ko) 2007-02-28
UA77002C2 (en) 2006-10-16
EP1427326A2 (en) 2004-06-16
EA008137B1 (ru) 2007-04-27
TNSN04015A1 (en) 2006-06-01
BR0211978A (pt) 2004-07-20
HRP20040170A2 (en) 2004-08-31
PE20030332A1 (es) 2003-04-05
CA2457745A1 (en) 2003-02-27
MXPA04001464A (es) 2005-02-17
KR20040043193A (ko) 2004-05-22
OA12651A (en) 2006-06-15
CN1541098A (zh) 2004-10-27
IS7137A (is) 2004-01-30
RS13204A (en) 2007-02-05
WO2003015608A3 (en) 2003-10-30
EA200400235A1 (ru) 2004-10-28
GEP20063868B (en) 2006-07-10
DE60229959D1 (de) 2009-01-02
WO2003015608A2 (en) 2003-02-27
ATE414512T1 (de) 2008-12-15
US20030216410A1 (en) 2003-11-20
IL159887A0 (en) 2004-06-20
AP2004002995A0 (en) 2004-03-31
SK1412004A3 (en) 2004-10-05
MA27060A1 (fr) 2004-12-20
AU2002329744B2 (en) 2007-08-30
NO20040516L (no) 2004-04-13
NZ530792A (en) 2005-09-30
JP2005501843A (ja) 2005-01-20
HUP0500424A3 (en) 2008-04-28
HUP0500424A2 (en) 2007-02-28
EP1427326A4 (en) 2005-06-08

Similar Documents

Publication Publication Date Title
AR038957A1 (es) Terapia de combinacion para el tratamiento del cancer
AR049127A1 (es) Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos
ES2653200T3 (es) Cannabinoides en combinación con agentes quimioterapéuticos no cannabinoides (por ejemplo, agentes de alquilación o SERM)
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
AR034118A1 (es) Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
AR065772A1 (es) Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.
AR051790A1 (es) Tratamiento de tuberculosis latente
ATE551060T1 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
RU2008114048A (ru) Комбинации, включающие ингибитор рецептора сэфр (сосудистого эндотелиального фактора роста) и агент, увеличивающий проницаемость
JP2009543768A5 (es)
CA2670422A1 (en) Spiroketone acetyl-coa carboxylase inhibitors
AR061743A1 (es) Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierro
AR042586A1 (es) 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
AR065844A1 (es) Derivados de 8-(heteroarilmetoxi)quinolina, moduladores selectivos de receptores de bradiquinina (bk) b2, composiciones farmaceuticas que los contienen y usos en terapia.
BG104372A (en) (benzodioxan, benzofuran or benzopyran) derivatives possessing fundus relaxing properties
ES2267591T3 (es) Combinaciones farmaceuticas que comprenden un antagonista del receptor p2t y melagatran.
TR199902367T2 (xx) 16-Hidroksi-11-(ikameli fenil)-estra-4,9-dien t�revleri.
RU2018134167A (ru) Комбинированная терапия для лечения острого миелоидного лейкоза
WO2014004676A1 (en) Use of faah inhibitors as neuroprotective agents in the cns
RU2006123939A (ru) Лечение остеопороза, связанного с терапией ингибиторами ароматазы
CO5200847A1 (es) Metodos y composiciones para tratar enfermedades y condiciones del ojo
WO2004096206A2 (en) Therapeutic combination of a cox-2 inhibitor and a tace inhibitor
AR037506A1 (es) Compuestos derivados de 4-fenil-4-[1h-imidazol-2-il]piperidina sustituida, sus profarmacos, composiciones farmaceuticas que comprenden dichos compuestos derivados, y uso de dichos compuestos derivados o composiciones farmaceuticas para la elaboracion de medicamentos
AP2001002181A0 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.
ES2879375T3 (es) Procedimientos de manejo del miedo condicionado con antagonistas del receptor de neuroquinina

Legal Events

Date Code Title Description
FB Suspension of granting procedure